source
- Roche reports phase 3 success for sefaxersen in IgA nephropathy, eyes accelerated approvalRoche announced that its experimental drug sefaxersen met the primary endpoint in a phase 3 trial for IgA nephropathy, showing reduced proteinuria versus placebo. The interim analysis at week 37 d…
- Boston biotech seed funding drops 40% as investors favor later-stage firmsBoston remains the world’s largest biotech hub, but early‑stage startups are feeling a sharp squeeze in capital. The average seed round for a pre‑clinical company in Massachusetts fell to $4.65 mi…